Novaliq GmbH
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
This first in-human, phase 2 proof of concept study aims to show that the formulation at two concentrations is safe and well tolerated over a period of 6 weeks.
Inclusion Criteria: * Be ≥18 years of age; * Provide written informed consent; * Be diagnosed with active non-infectious anterior uveitis requiring initiation or increase of topical steroids administration for the management of ocular inflammation; * Have an onset of symptoms within 4 weeks; Exclusion Criteria: * Have severe/serious ocular pathology in the study eye which may preclude study completion or interferes with trial assessment, in the judgement of the clinical Investigator; * Have a history of or a current ocular or periocular malignancy; * Have active intermediate or posterior uv…
high and low dose treatment will be compared over 6 weeks treatment